Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812286 | 0.77 | LMNA (0.39) | KMT2ANPC1LMNAPOLBRAB9A | |
| SCHEMBL811966 | 0.76 | LMNA (0.33) | KMT2ANPC1LMNAPOLBRAB9A | |
| SCHEMBL812270 | 0.72 | NPC1 (0.32) | KMT2ANPC1LMNAPOLBRAB9A | |
| SCHEMBL3512372 | 0.63 | GAA (0.50) | KMT2ANPC1LMNAPOLBRAB9A | |
| SCHEMBL812037 | 0.63 | PGR (0.34) | KMT2ALMNAALDH1A1 | |
| SCHEMBL822882 | 0.63 | LMNA (0.33) | KMT2ALMNASMN1; SMN2ALDH1A1PPARD | |
| SCHEMBL811968 | 0.62 | LMNA (0.47) | KMT2ALMNAALDH1A1ALOX15 | |
| SCHEMBL14066725 | 0.62 | MAPT (0.32) | KMT2ALMNAALDH1A1 | |
| SCHEMBL812048 | 0.62 | LMNA (0.38) | KMT2ANPC1LMNAPOLBRAB9A | |
| SCHEMBL811947 | 0.62 | RAB9A (0.33) | LMNARAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058210-B2 | Arylphenyl-substituted cyclic keto-enols | BAYER CROPSCIENCE AG (DE) | 2011-11-15 | — | — | US | disclosed |
| US-7718706-B2 | Arylphenyl-substituted cyclic keto-enols | BAYER AKTIENGESELLSCHAFT (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20100087320-A1 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO-ENOLS | LIEB FOLKER | 2010-04-08 | — | — | US | disclosed |
| US-20080081807-A1 | Arylphenyl-substituted cyclic keto-enols | LIEB FOLKER | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081807-A1 | Arylphenyl-substituted cyclic keto-enols | KCNE1, DDT, KCNQ3 | KMT2A 660/4885NPC1 4115/4885LMNA 2176/4885 |
| US-20100087320-A1 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO-ENOLS | KCNE1, DDT, KCNQ3 | KMT2A 660/4885NPC1 4115/4885LMNA 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.